ChromaDex Corporation (CDXC)
| Previous close | 3.7900 |
| Open | 3.7800 |
| Bid | 3.7800 x 200 |
| Ask | 3.8500 x 300 |
| Day's range | 3.7200 - 3.9000 |
| 52-week range | 1.2500 - 4.6500 |
| Volume | |
| Avg. volume | 297,264 |
| Market cap | 287.304M |
| Beta (5Y monthly) | 1.99 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0700 |
| Earnings date | 08 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.47 |
Simply Wall St.Should You Think About Buying ChromaDex Corporation (NASDAQ:CDXC) Now?
ChromaDex Corporation ( NASDAQ:CDXC ), might not be a large cap stock, but it led the NASDAQCM gainers with a...
ZacksPrecision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?
Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Business WireChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program
LOS ANGELES, March 26, 2024--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship Tru Niagen® product portfolio is now third-party verified through the Alkemist Assured™ testing transparency program by Alkemist Labs, a leading third-party testing laboratory known for its rigorous herbal and dietary supplement analysis. As the number one NAD+ supplement company in the US†, Tru Niagen features NIAGEN
